loading

Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten

pulisher
Nov 23, 2024

Connor Clark & Lunn Investment Management Ltd. Purchases 52,985 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Nov 23, 2024
pulisher
Nov 21, 2024

Oppenheimer & Co. Inc. Buys Shares of 48,139 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Nov 21, 2024
pulisher
Nov 19, 2024

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level - Yahoo! Voices

Nov 19, 2024
pulisher
Nov 18, 2024

Travere: Q3 Earnings Snapshot - AOL

Nov 18, 2024
pulisher
Nov 18, 2024

Los Angeles Capital Management LLC Has $391,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

3 Under-the-Radar Healthcare Companies - MSN

Nov 17, 2024
pulisher
Nov 15, 2024

When (TVTX) Moves Investors should Listen - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times

Nov 13, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies to Watch - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 10, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP

Nov 08, 2024
pulisher
Nov 08, 2024

Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics plans public stock offering - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Kapitalisierung:     |  Volumen (24h):